GlassScriptPhysician profile
Cristina Simpson
NPI 1710989983
$2,808.44
in general payments reported to CMS, 2019-2025
32 companies · $456 in 2025
The $456 reported for 2025 was more than what 78% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $434 · 2020: $196 · 2021: $326 · 2022: $487 · 2023: $405 · 2024: $505 · 2025: $456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,326 · Education: $40.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,326.34 |
| Education | $40.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $399.13 | 2019-2024 | Liletta |
| Evofem Biosciences, INC. | $362.33 | 2020-2025 | Phexxi, Solosec, Phexx |
| Mayne Pharma Commercial LLC | $230.70 | 2023-2025 | |
| Astellas Pharma US INC | $229.12 | 2020-2025 | Veozah, Myrbetriq |
| Axonics, INC. | $197.48 | 2023-2024 | Bulkamid, Axonics |
| Duchesnay USA Incorporated | $151.21 | 2019 | |
| Hologic Sales and Service, LLC | $149.91 | 2019 | |
| Becton, Dickinson and Company | $146.82 | 2021-2025 | Arista |
| Millicent US INC | $128.97 | 2019-2025 | Intrarosa, Femring |
| Shield Therapeutics INC | $101.22 | 2022-2025 | Accrufer |
| Avion Pharmaceuticals | $69.17 | 2020-2022 | |
| Agile Therapeutics, INC. | $68.41 | 2021-2024 | Twirla |
| Pfizer INC. | $64.62 | 2019-2025 | |
| Therapeuticsmd, INC. | $55.04 | 2019-2022 | |
| Coopersurgical, INC. | $54.43 | 2020-2024 | Paragard T 380a |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $52.21 | 2023-2024 | Nexplanon |
| Lupin INC. | $44.87 | 2019-2020 | |
| Smith+Nephew, INC. | $39.60 | 2022-2023 | Pico |
| Scynexis, INC. | $37.42 | 2022 | |
| Exeltis, USA INC. | $31.43 | 2024-2025 | Slynd |
| Baxter Healthcare | $28.94 | 2022 | |
| Biogen, INC. | $23.28 | 2024 | |
| Daiichi Sankyo INC. | $20.55 | 2019 | |
| Merck Sharp & Dohme LLC | $17.70 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.17 | 2021 | |
| Tactile Systems Technology INC | $16.53 | 2025 | Nimbl, Flexitouch Plus |
| Sumitomo Pharma America, INC. | $15.22 | 2025 | Gemtesa |
| Myovant Sciences INC. | $15.18 | 2021 | |
| Meditrina | $14.99 | 2022 | |
| Aspira Women'S Health INC | $13.48 | 2024 | Ova1 |
| Shire North American Group INC | $11.31 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cristina Simpson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.